SUBSCRIBE
SUBSCRIBE

Johnson & Johnson Family of Companies

NEWS
Job Trends
How Florida Landed Johnson & Johnson and the Promise of 500 New Jobs
October 24, 2016
 · 
2 min read
Biotech Bay
PETA Calls On Johnson & Johnson To End Sales Training Demonstration Involving Pigs
October 21, 2016
 · 
1 min read
Biotech Bay
Are Concerns About A Price War Between Johnson & Johnson And Pfizer “Overblown”?
October 20, 2016
 · 
1 min read
Biotech Bay
Pfizer’s Remicade Rudeness Shouldn’t Faze Johnson & Johnson
October 19, 2016
 · 
1 min read
Why AstraZeneca PLC CEO Took a Job His Friends Called a Suicide Mission
Deal Spree Continues as AstraZeneca PLC Inks $330 Million Pact With Johnson & Johnson
October 7, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
This Experimental Drug Could be Johnson & Johnson’s Next Blockbuster
October 6, 2016
 · 
2 min read
Deals
Johnson & Johnson Heiress Is Selling Her 600-Acre Farm For $28.5 Million
October 3, 2016
 · 
1 min read
What You Missed: Nippon Fine Chemical Formed Human Barricade to Stop FDA Employee
Pharm Country
FDA Places Clinical Hold on AML Drug Co-Developed by Johnson & Johnson and Genmab A/S
September 19, 2016
 · 
2 min read
Genetown
Johnson & Johnson Buying 100 Megawatts Of Texas Wind Power
September 19, 2016
 · 
1 min read
Load More
AWARDS
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
December 29, 2025
 · 
5 min read
Press Releases
European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
December 22, 2025
 · 
14 min read
Press Releases
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
December 19, 2025
 · 
6 min read
Press Releases
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
December 18, 2025
 · 
33 min read
Press Releases
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results - December 15, 2025
December 16, 2025
 · 
1 min read
Press Releases
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
December 16, 2025
 · 
4 min read
Press Releases
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
December 15, 2025
 · 
20 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
18 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
28 min read
Press Releases
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 9, 2025
 · 
1 min read
Load More